Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating sex as a predictive marker for response to bevacizuamb in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database
    Meeting Abstract

    Margalit, O.; Harmsen, W.; Shacham-Shmueli, E.; Voss, M.; Boursi, B.; Cohen, R.; Olswold, C.; Saltz, L.; Hurwitz, H.; Adams, R.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
    Meeting Abstract

    Hendifar, A.; Rosen, L.; McRee, A.; Cercek, A.; Basu-Mallick, A.; Spigel, D.; Tavazoie, S.; Rowinsky, E.; Szarek, M.; Gonsalves, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Meeting Abstract

    Tabernero, J.; Strickler, J.; Nakamura, Y.; Shitara, K.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Yoshino, T.; Siena, S.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
    Meeting Abstract

    Abou-Alfa, G.; Borbath, I.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D.; Roychowdhury, S.; Sadeghi, S.; Shroff, R.; Soto, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase III study (daNIS-2) of the antieTGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
    Meeting Abstract

    O'Reilly, E.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wainberg, Z.; Wang, L.; Gyambibi, N.; López, E.; Xu, K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Clinical and genomic characterization of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections in mRNA vaccinated health care personnel in New York City
    Journal Article

    Robilotti, E. V.; Whiting, K.; Lucca, A.; Poon, C.; Guest, R.; McMillen, T.; Jani, K.; Solovyov, A.; Kelson, S.; Browne, K.; more...
    Clinical Infectious Diseases (2022)

    Fulltext@MSK | Save
  • Associations of body fat distribution and cardiometabolic risk of testicular cancer survivors after cisplatin-based chemotherapy
    Journal Article

    Wibmer, A. G.; Dinh, P. C. Jr; Travis, L. B.; Chen, C.; Bromberg, M.; Zheng, J.; Capanu, M.; Sesso, H. D.; Feldman, D. R.; Vargas, H. A.
    JNCI Cancer Spectrum (2022)

    Fulltext@MSK | Save
  • Deciphering radiological stable disease to immune checkpoint inhibitors
    Journal Article

    Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Callahan, M. K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Journal Article

    Omuro, A.; Reardon, D. A.; Sampson, J. H.; Baehring, J.; Sahebjam, S.; Cloughesy, T. F.; Chalamandaris, A. G.; Potter, V.; Butowski, N.; Lim, M.
    Neuro-Oncology Advances (2022)

    Fulltext@MSK | Save
  • Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)
    Journal Article

    Galanis, E.; Anderson, S. K.; Twohy, E.; Butowski, N. A.; Hormigo, A.; Schiff, D.; Omuro, A.; Jaeckle, K. A.; Kumar, S.; Kaufmann, T. J.; more...
    Neuro-Oncology Advances (2022)

    Fulltext@MSK | Save